JMJD6 and renal cell carcinoma: C646, a histone acetyltransferase inhibitor targeting p300, was selected to treat RCC cells, and we found a significant decrease in JMJD6 mRNA levels in a time‐ and dose‐dependent manner (Figures 4E, 4F, and S2E).